ASHEVILLE, N.C.,
June 26,
2024 /PRNewswire/ -- DiaCarta,
Inc. ("DiaCarta"), a pioneer in developing innovative
molecular technologies to transform patient care by providing
effective precision diagnostics using liquid biopsy in cancer and
infectious diseases has established a strategic collaboration with
Capstone Health Alliance, one of the largest regional group
purchasing organizations (GPO) in the US healthcare sector. This
new collaboration brings together powerful technologies to enhance
patient care.
DiaCarta's key product
portfolio includes its trailblazing RadTox™ test, a blood test that monitors
tumor response & progression following cancer treatment by
monitoring changes in cell free circulating DNA (cfDNA) levels.
This serves to personalize radiation and chemotherapy, mitigate
adverse events, and enhance patient care. The state of Florida has deployed the RadTox™ test
statewide to be performed between Radiotherapy or Chemotherapy
doses for real time detection of treatment response or resistance.
The Oncuria bladder cancer tests are designed for the detection of
bladder cancer, monitoring of bladder cancer recurrence, and
revolutionizing the prediction of BCG therapy response
for non-muscle invasive bladder cancer (NMIBC) patients, empowering
clinicians with personalized treatment strategies. The
VEXAS syndrome
test is a groundbreaking, highly
sensitive test that is used to diagnose a
rare autoimmune condition that causes inflammation throughout the
body caused by a mutation in the UBA1 gene.
The ColoScape™ Colorectal Cancer Mutation Detection
Blood Test detects methylations highly specific to CRC and
associated genetic mutations with high sensitivity to advanced
adenomas.
"We are excited at the opportunity to combine forces with DiaCarta's
innovative products to help Capstone Health Alliance members and
their patients, with early detection, diagnosis & management of
cancer and critical disease states," said
Fred J. Pane, R. Ph.,
FASHP, FABC, Vice President, Pharmacy Services
at Capstone. "These tests will enhance treatment and ensure
effective use of drugs such as BCG, which is in short supply and
ensure cost efficiencies in patient care."
"We are thrilled to announce our collaboration with Capstone
Health GPO to provide its vast network of
members access to our novel
molecular oncology diagnostic tests," said Ram Vairavan Ph D Senior
Vice President at DiaCarta. "Our goal is to enhance patient care by
providing diagnostic solutions that help physicians choose the
right therapy, monitor treatment response and ultimately save
lives."
About Capstone Health Alliance
Headquartered in Asheville, NC,
Capstone Health Alliance is a leading regional group purchasing
organization (GPO) that collaborates with hundreds of hospitals and
thousands of healthcare providers nationwide. Our primary goal is
to deliver tangible savings and provide actionable data to enable
informed supply chain decisions. Capstone is
committed to helping our Members
reduce costs, enhance quality,
and foster the exchange of best
practices. We achieve this through
our unwavering dedication to price parity, offering
consistent savings regardless of organizational size or location.
Moreover, our Members gain exclusive access to educational
opportunities and benefit from the expertise of our
dedicated team of supply
chain professionals. To learn more about Capstone
Health Alliance and how our innovative solutions can
benefit your organization, please visit
capstonehealthalliance.com.
About DiaCarta
DiaCarta is a pioneering molecular diagnostics company
dedicated to advancing precision medicine
through innovative liquid biopsy technologies. With a focus on
improving patient outcomes across diverse oncology indications,
DiaCarta's portfolio of cutting-edge assays empowers clinicians
with
actionable insights for personalized treatment strategies. For more information, visit www.diacarta.com.
Contacts:
|
|
Anne Vallerga, PhD, MBA
Vice Presidents, External Affairs
DiaCarta
379670@email4pr.com
(650) 333-3152
diacarta.com
|
Tracey Johnston-Crum
Associate Vice President, Marketing and PR
Capstone Health Alliance
379670@email4pr.com
(828) 216-5813
capstonehealthalliance.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/diacarta-and-capstone-health-alliance-collaborate-to-bring-revolutionary-diagnostic-tests-to-enhance-patient-care-302182660.html
SOURCE DiaCarta, Inc.